On May 5, 2022, Curebase, Inc. closed the transaction. The round of funding led by new investor Industry Ventures, L.L.C. The transaction included participation from new investors, aCrew Capital, Wil LLC, Positive Sum Advisors, Gilead Sciences, Inc., and Gaingels, LLC, existing investors GGV Capital, LLC, Bold Capital Partners, and Xfund Management Company, LLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.94 USD | +0.79% | -1.51% | -18.60% |
Apr. 29 | Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 | MT |
Apr. 26 | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.60% | 81.58B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Curebase, Inc. announced that it has received $40.000011 million in funding from a group of investors